Sudubrilimab (HS636) is an IgG1-kappa monoclonal antibody targeting PD-L1. This antibody is uniquely engineered with a fusion to the C-terminus of the heavy chain incorporating a TGF-??1 receptor II ectodomain (TGFBR2-ECD). This design enables Sudubrilimab to simultaneously inhibit the PD-1/PD-L1 interaction and modulate TGF-?? activity, effectively countering the immunosuppressive effects within the tumor microenvironment. This dual functionality makes it a valuable tool for research into cancer immunotherapy mechanisms and potential therapeutic interventions.
Sudubrilimab (HS636) is an IgG1-kappa monoclonal antibody targeting PD-L1. This antibody is uniquely engineered with a fusion to the C-terminus of the heavy chain incorporating a TGF-??1 receptor II ectodomain (TGFBR2-ECD). This design enables Sudubrilimab to simultaneously inhibit the PD-1/PD-L1 interaction and modulate TGF-?? activity, effectively countering the immunosuppressive effects within the tumor microenvironment. This dual functionality makes it a valuable tool for research into cancer immunotherapy mechanisms and potential therapeutic interventions.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
